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Abstract
Liver cirrhosis results from chronic hepatic damage and is characterized by derangement of the organ architecture
with increased liver ﬁbrogenesis and defective hepatocellular function. It frequently evolves into progressive hepatic
insufﬁciency associated with high mortality unless liver transplantation is performed. We have hypothesized that the
deﬁciency of critical nutrients such as essential omega-3 fatty acids might play a role in the progression of liver
cirrhosis. Here we evaluated by LC-MS/MS the liver content of omega-3 docosahexaenoic fatty acid (DHA) in cirrhotic
patients and investigated the effect of DHA in a murine model of liver injury and in the response of hepatic stellate
cells (HSCs) (the main producers of collagen in the liver) to pro-ﬁbrogenic stimuli. We found that cirrhotic livers exhibit
a marked depletion of DHA and that this alteration correlates with the progression of the disease. Administration of
DHA exerts potent anti-ﬁbrogenic effects in an acute model of liver damage. Studies with HSCs show that DHA inhibits
ﬁbrogenesis more intensely than other omega-3 fatty acids. Data from expression arrays revealed that DHA blocks
TGFβ and NF-κB pathways. Mechanistically, DHA decreases late, but not early, SMAD3 nuclear accumulation and
inhibits p65/RelA-S536 phosphorylation, which is required for HSC survival. Notably, DHA increases ADRP expression,
leading to the formation of typical quiescence-associated perinuclear lipid droplets. In conclusion, a marked depletion
of DHA is present in the liver of patients with advanced cirrhosis. DHA displays anti-ﬁbrogenic activities on HSCs
targeting NF-κB and TGFβ pathways and inducing ADPR expression and quiescence in these cells.
Introduction
Persistent liver damage causes repeated boosts of cell
death and regeneration, ultimately leading to a distortion
of liver architecture known as liver cirrhosis. Cirrhosis is
characterized by the formation of regenerative hepato-
cellular nodules surrounded by a ﬁbrous tissue. Hepato-
cellular dedifferentiation and increased collagen
deposition by activated hepatic stellate cells (HSCs)
constitute the pathophysiologic landmark of liver cir-
rhosis1. This condition is associated with defective liver
function and increased portal pressure and tends to pro-
gress to stages of more severe hepatic insufﬁciency and
portal hypertension, resulting in complications such as
portal systemic encephalopathy, gastrointestinal bleeding,
malnutrition and ascite formation.
The characterization of factors that might promote
cirrhosis progression is of considerable clinical interest.
We have reasoned that in advanced liver cirrhosis a
number of disturbances such as porto-systemic shunting,
inadequate dietary intake, impaired intestinal absorption,
compromised integrity of the intestinal barrier, inﬂam-
mation and altered metabolism might deprive liver cells of
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essential nutrients2,3, and that this defect could potentially
inﬂuence the evolution of the disease.
Omega-3 polyunsaturated fatty acids (ω3-PUFAs) are
essential fatty acids that cannot be synthesized by the
body and need to be obtained from the diet. The most
relevant ω3-PUFA compounds are eicosapentaenoic acid
(EPA), docosahexaenoic acid (DPA) and docosahexaenoic
acid (DHA). These molecules display potent anti-
inﬂammatory effects in different conditions by inhibiting
leukocyte chemotaxis and blocking the production of
eicosanoids and pro-inﬂammatory cytokines4. Moreover,
ω3-PUFAs impact cell function by inﬂuencing cell
membrane composition, disrupting lipid rafts, activating
G-coupled protein receptors, acting as precursors of pro-
resolving mediators and modulating key transcription
factors such as PPARs, SREBP1, ChREB, NF-κB and
LXR5. Accordingly, hepatic DHA abundance may likely
modulate the liver response to injury. However, although
some studies in cirrhotic patients have shown a reduction
in the circulating levels of ω3-PUFA6,7, there is no
information at all regarding DHA values in the cirrhotic
liver, the site where this omega-3 would display its tissue
homeostatic effects.
Fat-1 transgenic mice (which are capable of producing
ω3-PUFA from ω6-PUFA) are protected against multiple
liver insults such as alcohol and high-fat diet (HFD), non-
alcoholic steatohepatitis (NASH) and DEN-induced
HCC8–11. Moreover, oral administration of ω3-PUFA
displays protective activities in several animal models
of chronic hepatic damage, including NASH and
CCl4-induced liver ﬁbrosis. In these conditions ω3-PUFAs
decrease steatosis, inﬂammation and ﬁbrosis12–15. The
anti-ﬁbrotic effect of these compounds is in line with their
ability to reduce COL1A1 expression by TGFβ-stimulated
HSCs14. However, the molecular mechanisms underlying
this effect remain elusive.
In the present study, we show that the cirrhotic liver is
strikingly depleted of DHA in parallel with the progression
of the disease and that DHA reverts HSCs to quiescence
and inhibits the ﬁbrogenic responses to TGFβ stimulation
and NF-κB activation by affecting SMAD3 nuclear accu-
mulation and p65/RelA S536 phosphorylation.
Results
DHA is deﬁcient in cirrhotic livers
DHA has been reported to be decreased in the plasma of
cirrhotic patients6,7, but there is no information concerning
its values in the cirrhotic liver, a site where DHA biological
effects could be crucial in maintaining tissue homeostasis.
Thus, we used liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) to determine DHA, DPA and ara-
chidonic acid (AA) levels in liver samples from 14 cirrhotic
patients and in 12 normal liver specimens (Supplementary
table 1). We found that DHA, but not AA or DPA, values
were markedly reduced in the cirrhotic liver tissue (Fig. 1a
and Supplementary Fig. 1). Accordingly, the ratio DHA/AA
in hepatic tissue was signiﬁcantly diminished in cirrhotic
patients compared to controls (Fig. 1a). Interestingly, the
stratiﬁcation of the patients according to Child-Pugh score
indicated that DHA abundance decreased in association
with the progression of the disease (Fig. 1b). DHA and the
ratio DHA/AA were also signiﬁcantly decreased in ﬁbrotic
mouse livers compared to control livers (Fig. 1c). A similar
decrease in hepatic DHA was also observed in TAA-treated
ﬁbrotic mice (n= 7; **p < 0.01; data not shown).
DHA has been shown to reduce oxidant stress and
ﬁbrogenesis in the liver in mouse models of NASH or
chronic CCl4 administration
14,16. Although DHA was
found to inhibit TGFβ-induced COL1A1 expression by
human Lx2 stellate cells, the molecular mechanisms
underpinning DHA anti-ﬁbrogenic activity remain elu-
sive. To better understand how DHA modulates liver
ﬁbrosis and the response to injury, we ﬁrst studied the
effect of DHA in a model of acute liver injury (Fig. 2a).
Animals were challenged with CCl4 (days −3 and 0) and
given by intragastric route (days −2, −1, 0 and+ 1) DHA
in sesame oil or vehicle alone, and were sacriﬁced at 24
and 48 h after the last CCl4 dose. At 24 h we found that
hepatic DHA levels were increased in those animals given
DHA but serum transaminases (ALT and AST), serum
bilirubin and hepatic COL1A1, and αSMA mRNA levels
showed similar values in both DHA-treated and
-untreated mice, indicating comparable tissue damage in
the two groups and no signiﬁcant effect of DHA therapy
at that time (Fig. 2b, c and data not shown). However, one
day later, DHA-treated mice showed a marked reduction
of COL1A1 and αSMA mRNAs and a diminished number
of αSMA-positive cells compared to controls (Fig. 2c–e).
These data suggest that DHA does not prevent hepato-
cellular damage but greatly attenuates the activation and
ﬁbrogenic response of HSCs in this model. Therefore, we
proceeded to explore the biological effects of DHA on this
cell population.
DHA exceeds other ω3-PUFAs in its ability to inhibit HSC
activation and proliferation and to induce HSC quiescence
In both human Lx2 stellate cells and primary mouse
HSCs (mHSCs), we found that DHA reduced HSC pro-
liferation and expression of pro-ﬁbrogenic factors
(COL1A1, αSMA and PDGFRβ) in a dose-dependent
manner (Supplementary Fig. 2). In addition, DHA
markedly enhanced the expression of ADRP, a molecule
that promotes lipid droplet formation (Fig. 3a). Impor-
tantly, DHA was more efﬁcient at inducing these effects
than other ω3-PUFAs (Fig. 3b, c). DHA is metabolized to
lipid mediators with anti-inﬂammatory properties, such
as Maresin, Resolvin D1 or 17(R)-Resolving D1, an
aspirin-triggered epimer of Resolvin D1. However,
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treatment of Lx2 cells with these mediators did not affect
the levels of COL1A1 or αSMA mRNAs (data not shown).
As a whole, our results indicate that DHA is the strongest
anti-ﬁbrotic ω3-PUFA and that these effects could be
exerted directly by DHA. Of note, Lx2 cells treated with
DHA showed a marked enrichment in cytoplasmic lipid
droplets, a characteristic feature of quiescent HSCs
(Fig. 3d).
Transcriptome analyses reveal that DHA modulates plural
cell response pathways in both Lx2 cells and mHSCs
Ingenuity pathway analysis of microarray data obtained
from mHSCs and Lx2 cells indicated that the most highly
affected processes in DHA-treated cells were HSC acti-
vation/hepatic ﬁbrosis, NRF2-mediated oxidative stress
response and ATF4-mediated unfolded protein response
(UPR) (Fig. 4a). The most signiﬁcant upstream regulators
of DHA-altered genes were TGFβ (inhibited), ATF4
(activated), TP53 and TNFα (Fig. 4b). Thus, our data
showed that DHA downregulated pro-ﬁbrogenic factors
(COL1A1, αSMA, PDGFRβ and TGFβ) and cell survival
molecules (cMET) and upregulated anti-ﬁbrogenic and
cytoprotective factors (HGF) in both mHSCs (Fig. 4c) and
Lx2 cells (Supplementary Fig. 3). In addition, DHA also
enhanced the expression of NRF2 target genes (such as
HMOX1) and ATF4-dependent genes (such as TRIB3)
(Fig. 4d). Consistently, DHA-treated Lx2 cells increased
eIF2α phosphorylation (an event occurring during UPR)
and mobilization of NRF2 to cell nuclei (Fig. 4e, f). These
observations led us to analyze whether the effects on
NRF2 and UPR pathways were implicated in DHA anti-
ﬁbrogenic activity. With this aim, we overexpressed or
knocked down (using siRNA) NFR2 in Lx2 cells and
analyzed the expression of HMOX1, COL1A1 and αSMA.
We found that NFR2 overexpression enhanced HMOX1
mRNA levels but did not affect COL1A1 or αSMA
expression. Similarly, NRF2 knockdown did not attenuate
DHA-mediated inhibition of pro-ﬁbrogenic factors (Sup-
plementary Fig. 4a–b). Furthermore, increasing eIF2α
phosphorylation and thus ATF4 activation with salubrinal
or inhibiting ATF4 activation with ISRIB did not affect the
levels of COL1A1 or αSMA mRNAs and did not alter the
suppressive properties of DHA on COL1A1 and αSMA
expression (Supplementary Fig. 4c-d). These observations
suggested that DHA anti-ﬁbrogenic activity was not
mediated by the NRF2 or ATF4 pathway. Therefore, we
focused on the analysis of the effects of DHA on TGFβ
and NF-κB pathways.
Fig. 1 DHA levels decrease in cirrhotic livers. DHA and AA levels were determined by LC-MS/MS in liver samples from healthy and cirrhotic
patients (a) or in liver tissue from control or CCl4-treated mice (c). b DHA levels in patients stratiﬁed according to Child-Pugh score
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DHA modulates nuclear SMAD3 accumulation and
abrogates the induction of TGFβ delayed target genes
As mentioned, transcriptomic analyses suggested that
DHA treatment of HSCs inactivates the TGFβ pathway.
The TGFβ canonical pathway requires phosphorylation of
the SMAD2/3 complex, binding to SMAD4 and nuclear
translocation of the hetero-oligomeric complex. We
observed that DHA blocked the production of luciferase
from the SBE4-Luc plasmid, which requires SMAD3 for
its expression (Fig. 5a). Kinetic experiments showed that
TGFβ treatment induced the phosphorylation of SMAD3
and that DHA did not affect the total levels of SMAD3 or
phosphorylated SMAD3 (p-SMAD3) up to 24 h post
TGFβ treatment (Fig. 5b). However, while the nuclear
levels of SMAD3 were similar between cells incubated and
those not incubated with DHA at early times (3 h) post
TGFβ treatment, at a later time (24 h), a drastic decrease
in the amount of nuclear SMAD3 was observed in DHA-
treated cells (Fig. 5c). In agreement with these results, the
expression of targets induced at early times post TGFβ
treatment, such as SERPINE1/PAI-I or SMAD7, was not
affected by DHA, while delayed targets, such as COL1A1
or αSMA, showed a highly signiﬁcant decrease in DHA-
incubated cells compared to controls (Fig. 5d). Similar
results were observed at 24 and 48 h post TGFβ treatment
(data not shown).
DHA decreases phosphorylation and activity of the NF-κB
subunit p65/RelA
DHA modulates the NF-κB pathway in HSCs, as tran-
scriptome analyses in DHA-treated cells showed TNFα as
a top upstream regulator (Fig. 4). We observed that DHA
drastically reduces the levels of pro-inﬂammatory tran-
scripts CXCL10, CXCL9 or TNFα in Lx2 cells stimulated
with TNFα for 6 or 40 h (Fig. 6a). Using total extracts
from cells treated with TNFα for 15 min, we observed that
DHA does not affect the levels of the p65/RelA subunit of
NF-κB, but drastically decreases p65/RelA serine 536
phosphorylation (p-p65(S536)) (Fig. 6b). When nuclear
and cytoplasmic fractions were evaluated, we found that
most components of the NF-κB pathway (IKKs, IκBα,
IκBβ, p65, and p50) were not altered by DHA treatment
Fig. 2 DHA has anti-ﬁbrogenic effects in an acute liver damage model. a Schematic of the experiment. b Serum ALT and AST. c COL1A1 and
αSMA expression. d IHQ of αSMA in livers from mice sacriﬁced 48 h after the last dose of CCl4. Scale bar, 100 μm. e Quantiﬁcation of the αSMA-
positive area with ImageJ software. Results shown are from a representative experiment out of the three experiments performed
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(Fig. 6c). The exception was p-p65(S536), which
decreased in both nuclear and cytoplasmic extracts of
DHA-treated cells. Similar results were observed in cells
treated with TNFα for 6 h (data not shown).
The phosphorylation of p65(S536) can be mediated by
several kinases, including IKKβ17. Although it has been
described that DHA suppresses IKKβ phosphorylation
and activity18, this is not the case in HSCs. Lx2 cells
transfected with a plasmid that expresses a constitutively
active IKKβ (pIKKB-ON) showed an increase in the levels
of CXCL10 mRNA and other pro-inﬂammatory tran-
scripts compared to control cells (Fig. 7a and data not
shown). Surprisingly, despite the strong activation of the
NF-κB pathway obtained under constant IKKβ activation,
DHA treatment blocked the induction of these pro-
inﬂammatory genes. Similar results were observed in Lx2
cells transfected with a plasmid expressing wild-type
p65/RelA (Fig. 7b). Expression of a mutant S536A
p65/RelA that cannot be phosphorylated does not induce
CXCL10 levels but can diminish the inhibitory effect of
DHA. This indicates that the regulation of p65(S536)
phosphorylation by DHA is required to diminish the
transcription of target genes. In agreement, western blot
analyses indicated that overexpressed wild-type and
Fig. 3 DHA induces stronger anti-ﬁbrogenic effects than other FAs. a αSMA, COL1A1 and ADRP expression in primary mHSCs plated for 3 days
and treated with DMSO or 100 µM DHA for 48 h. b–d Lx2 cells treated with DMSO or with 50 µM of the indicated PUFAs. αSMA, COL1A1 and ADRP
expression at 24 h (b), MTT assay at indicated times (c) and lipid droplet content at 72 h (d). Scale bar, 20 μm. Experiments were performed two (a, b)
or three (c) times
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mutant p65/RelA versions are efﬁciently transported to
the nucleus of HSCs and that DHA can dephosphorylate
exogenous wild-type p65/RelA (Fig. 7c and data not
shown). Interestingly, DHA-mediated regulation of
p65/RelA affects the expression of pro-ﬁbrogenic factors,
as the levels of COL1A1 and αSMA transcripts increase in
HSCs that overexpress wild-type but not S536A mutant
p65/RelA (Fig. 7d). DHA treatment decreases the levels of
phosphorylated p65(S536) and results in lower levels of
pro-ﬁbrogenic factors. Altogether, our results indicate
that DHA inhibits the NF-κB pathway by decreasing p65
(S536) phosphorylation even under conditions of strong
pathway induction by constant IKKβ activation or by the
overexpression of wild-type p65/RelA. In addition, p65/
RelA activity contributes to the expression of pro-
ﬁbrogenic factors in HSCs.
Discussion
One of the relevant ﬁndings of the present study was the
presence of a profound DHA deﬁciency in the liver of
cirrhotic patients. Notably, as liver cirrhosis progresses,
liver depletion of DHA worsens in such a manner that
Child-Pugh C patients have about half of the values found
in normal hepatic tissue. The reasons for this defect could
be diverse. ω3-PUFAs cannot be synthesized by mammals
and need to be obtained from the diet. Thus, although a
deﬁcient diet may be a potential cause of low liver DHA
content, other pathogenic factors, including malabsorp-
tion, changes in intestinal microbiota and the presence of
porto-systemic shunts, may enter into play. Indeed, in
liver cirrhosis, the intestinal barrier is disturbed and the
composition of gut microbiota is deeply altered the dys-
biosis being more intense as the disease progresses19. It
seems possible that the pro-inﬂammatory milieu in the
gut wall and the overgrowth of pathogenic bacteria may
compromise DHA bioavailability. Interestingly, it has
been shown that DHA contributes to protecting the
integrity of the intestinal wall and restoring gut micro-
biota composition20. This is a relevant observation as
dysbiosis has been implicated in the pathophysiology of
liver cirrhosis19,21. On the other hand, a deﬁciency of ω3-
PUFA may enhance microbiota alteration. Another
important factor contributing to liver depletion of DHA is
the presence of porto-systemic shunts in patients with
advanced liver cirrhosis and portal hypertension as the
resulting reduction in portal blood ﬂow to the liver may
reduce hepatic inﬂow of crucial nutrients including DHA.
In cirrhotic patients, DHA depletion may have a sig-
niﬁcant impact on liver tissue homeostasis, likely
favouring ﬁbrosis progression. Indeed, our data in mouse
models of acute CCl4-induced liver damage indicate that
DHA does not reduce hepatocellular damage while it
Fig. 4 DHA affects several signaling pathways in Lx2 and mHSCs. a, b Differentially expressed genes (B > 0) from expression arrays were
scrutinized by Ingenuity analysis to identify the altered top canonical pathways (a) and the top upstream regulators (b). The p value and the
prediction state are indicated. c Heat map of the differentially expressed genes in mHSCs from the “Hepatic Fibrosis/Hepatic Stellate Cell Activation”
pathway. d–f Lx2 cells were control-treated or incubated with 50 µM DHA. HMOX1 and TRIB3 expression after 48 h (d). Data are means ± SD from two
experiments. Nuclear NRF2 accumulation after 6 h (e). EIF2α and phosphorylated EIF2α (pEIF2α) after 6 h (f)
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strongly attenuates HSC activation and αSMA and
COL1A1 expression. The anti-ﬁbrogenic effects of DHA
have also been shown in animal models of chronic liver
damage14,16, and in line with these ﬁndings it has been
reported that DHA dampens the response of HSCs to
TGFβ14. However, the molecular basis underlying these
effects has not been characterized.
Our transcriptional analysis of primary mHSCs and Lx2
cells showed that DHA inhibits TGFβ and NF-κB path-
ways while inducing NRF2-dependent antioxidant
response and the ATF4 branch of the UPR (Fig. 4).
Regarding the last two biological processes, previous
studies have shown that DHA promotes nuclear accu-
mulation of NRF2, a factor that opposes TGFβ signaling
Fig. 5 DHA decreases TGFβ-induced expression of COL1A1 and αSMA by affecting the nuclear accumulation of SMAD3. Lx2 cells treated
with DMSO (C-), 30 µM of DHA (D), 7.5 ng/ml TGFβ (T) or both DHA and TGFβ (DT) for the indicated times. a Luciferase levels measured 24 h after
treatments in cells previously transfected with the SBE-Luc plasmid. Data are mean ± SD from two experiments. b GAPDH, SMAD3 and p-SMAD3
proteins in total extracts. c C23 and SMAD3 proteins in nuclear extracts. d SERPINE1, SMAD7, COL1A1 and αSMA mRNA levels. Data are mean ± SD
from two experiments
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by binding to SMADs and inhibiting transactivation22–26.
Further, DHA has also been reported to cause ER stress
and eIF2α phosphorylation27, and this effect may stimu-
late ﬁbrogenesis28–30. However, in experiments directed
to blocking or enhancing these two pathways we found
that neither NRF2 nor ATF4 mediates in a signiﬁcant
manner the suppressive effect of DHA on COL1A1 and
αSMA expression by HSCs. Thus, it seems plausible that
DHA may deploy its anti-ﬁbrogenic activity by interfering
with TGFβ and NF-κB signaling.
TGFβ is a potent inducer of pro-ﬁbrogenic genes, such
as COL1A1, αSMA and PDGFRβ, in HSCs. Moreover,
TGFβ represses ADRP, a molecule that favors HSC
quiescence and promotes lipid droplet formation by
allowing the liberation of lipid drops from the ER mem-
brane31,32. Our transcriptome analysis indicated that
DHA inhibited the TGFβ pathway, attenuated ﬁbrogen-
esis and reverted HSC activation (Fig. 4a, b). In fact, one
of the key genes upregulated by DHA was ADRP.
Accordingly, Lx2 cells treated with DHA were found to
Fig. 6 DHA decreases p65/RelA Ser536Ph. Lx2 cells were pretreated with DMSO or 30 µM DHA for 2 h and then incubated or not with 35 ng/ml
TNFα for 15 min (b, c), 6 or 40 h (a). CXCL10, CXCL9 and TNFα mRNA levels (a). Data are mean ± SD from three experiments. NF-κB signaling pathway
proteins in total (b), nuclear and cytoplasmic (c) extracts. GAPDH and C23 were used as loading and fractionation controls
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accumulate lipid drops in the cytoplasm, a characteristic
feature of quiescent HSCs (Fig. 3d).
TGFβ functions by the activation and nuclear translo-
cation of the SMAD2/3/4 factors. Then, SMADs bind the
SBE (SMAD-binding element) sequence and allow the
transcription of target genes. Several of these are induced
very rapidly after stimulation with TGFβ. These early
genes have been suggested to be pure SMAD respon-
ders33. The initial TGFβ response is followed by a sec-
ondary wave of transcription that may require co-
operation of SMADs with other transcription factors
such as STAT3, which help collagen expression34. Inter-
estingly, we found that in HSCs DHA does not alter the
initial transcriptional response to TGFβ but decreases the
expression of the genes that are induced at 24 h. This
observation was paralleled by changes in SMAD3 content
in the cell nuclei as its values were comparable to controls
at 6 h but markedly reduced at 24 h. This late nuclear
depletion of SMAD3 by DHA causes the repression of
pro-ﬁbrogenic factors such as COL1A1 or αSMA (late
genes) without affecting the levels of the TGFβ inhibitor
SMAD7 (early gene). It should be noted that SMAD7
plays a critical role as an anti-ﬁbrogenic factor by binding
to the TGFβ receptor and blocking the association,
phosphorylation and activation of the SMAD2/SMAD3
complex35.
In addition to TGFβ-induced pro-ﬁbrogenic factors,
activated HSCs (aHSCs) also secrete and sense inﬂam-
matory mediators. In fact, the NF-κB pathway is required
for activation and survival of HSCs and for increasing the
sensitivity of these cells to TGFβ36. In aHSCs, TNFα,
angiotensin II, and other factors trigger IKKβ, which
phosphorylates p65(S536). This transcription factor leads
to the expression of pro-survival molecules and fresh
angiotensin II, required to maintain a positive regulatory
loop that guarantees aHSC survival37. The loop results in
the constitutive activation of IKKβ and constitutive levels
of p-p65(S536), characteristic of aHSCs. Increased apop-
tosis of aHSCs is observed when this pathway is blocked
by antagonists of angiotensin receptors or inhibitors of
IKKβ37,38. Here we show that DHA blocks this pathway by
decreasing p65(S536) phosphorylation in an IKKβ-
independent manner (Figs. 6 and 7). This is different
from what has been described in most cells, where DHA
Fig. 7 Phosphorylation of p65/RelA at S536 is essential for CXCL10 induction and displays pro-ﬁbrogenic effects in Lx2 cells. a CXCL10
expression in cells transfected with a control plasmid (pC) or a plasmid expressing the constitutive active form of IKKβ (pIKKb-ON) and mock treated
or treated with 30 µM DHA for 24 h. b–d Lx2 cells were transfected with a control plasmid (pC), a plasmid expressing wild-type p65/RelA (pWT) or a
mutant S536A that cannot be phosphorylated (pA). At 24 h, the cells were mock treated or treated with 30 µM DHA for 24 h. CXCL10 (b) and COL1A1
and αSMA expression (d). Data are means ± SD from three experiments. p65/RelA and p-p65/RelA(S536) protein in total extracts (c)
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decreases the activity of IKKβ and/or reduces the phos-
phorylation and degradation of the negative regulator
IκBα, thus hindering nuclear translocation of NF-κB39–42.
By decreasing p65(S536) phosphorylation, DHA blocks
ﬁbrosis development in different manners, including
reduced production of pro-ﬁbrogenic factors (p65 phos-
phorylation in S536 is required for COL1A1 and αSMA
expression by aHSC) and induction of aHSC apoptosis
(p65 phosphorylation in S536 is an essential survival
factor). Finally, DHA acting on HSCs also decreases
inﬂammation by reducing the secretion of factors such as
CXCL10, a pro-inﬂammatory chemokine that recruits
leukocytes after liver injury and contributes to aHSC
survival, migration and liver ﬁbrosis development43,44.
As mentioned, DHA has demonstrated beneﬁts in dif-
ferent animal models of liver damage12–15. These data
stimulated clinical trials using ω3-PUFAs (EPA or com-
binations of DHA and EPA) in patients with non-
alcoholic fatty liver disease (NAFLD) or NASH. These
studies have shown positive effects on hepatic steatosis
but have not demonstrated signiﬁcant and reproducible
effects on ﬁbrosis45–52. It should be noted that these
clinical trials have used a mix of ω3-PUFAs at doses lower
than those applied in animal studies. As DHA shows
higher anti-ﬁbrogenic activity than other ω3-PUFAs, it
seems possible that using pure DHA at higher doses could
be necessary to obtain anti-ﬁbrogenic effects in patients
with liver disease. Also, combinations of DHA and
therapies aimed at restoring gut microbiota could afford
better therapeutic results.
Materials and methods
Human samples, animal models, serum biochemistry and
immunohistochemistry
Human liver samples (Supplementary Table 1) and data
from patients with or without alcoholic cirrhosis were
provided by the Biobank of the University of Navarra and
were processed following standard operating procedures
approved by the Ethical and Scientiﬁc Committees. Ani-
mal studies were performed following the regulations of
the Animal Care Ethical Committee from the University
of Navarra. Mice were housed 4–6 per cage in a facility in
which temperature (21 °C), humidity and light cycle (12 h
light/dark) were controlled and had ad libitum access to
food and water. C57 male mice (8 weeks old) were
obtained from Harlan (Oxon, UK). For CCl4-induced
chronic liver damage two independent experiments were
performed. Liver ﬁbrosis was developed by intraperitoneal
(IP) injection of 0.75 µl/g CCl4 (Merck) twice per week for
4 (n= 4) or 6 (n= 4) weeks. For TAA-induced chronic
liver damage, mice received IP injections of 200 mg/kg
TAA, 3 per week for 8 weeks (n= 7). Fibrosis was con-
ﬁrmed in all animals by Sirius red staining and by eva-
luation of COL1A1 and αSMA mRNA levels. Acute liver
injury was induced with two doses of 1 µl/g CCl4 (2:5, v/v
in sesame oil (Sigma S3547)) administered by IP injection
(Fig. 2a). DHA treatment was performed by daily intra-
gastric administration of 450mg/kg DHANua (Nua Bio-
logical Innovations S.L) diluted 1:3, v/v in sesame oil and
starting from 24 h after the ﬁrst dose of CCl4. Similar
results were observed when, instead of sesame oil, DHA
was mixed thoroughly with phosphate buffered saline
(PBS) to form an emulsion. Serum and liver samples were
collected for further analyses. Serum aspartate transami-
nase (AST) and alanine transaminase (ALT) levels were
determined (ABX diagnostics) in a Hitachi autoanalyzer
(Roche). Liver tissues were ﬁxed overnight in for-
maldehyde (252931.1211 Panreac), dehydrated in ethanol,
and embedded in parafﬁn according to standard proce-
dures. Sections were prepared and stained with a primary
antibody against αSMA (Sigma, A2547).
PUFA determination in human and mouse livers by
LC-MS/MS
Liver tissue (25 mg) was homogenized in 100 μl of PBS
with 0.01% BHT (2,6-di-tert-butyl-4-methylphenol,
Merck Ref. 822021). Protein concentration was deter-
mined using the Bradford assay (Bio-Rad Ref. 500–0006).
Lipid extraction was carried out following the protocol
described by Bligh and Dyer53. DHA and AA were
quantiﬁed using multiple reaction monitoring performed
in a linear ion trap triple quadrupole mass spectrometer
(QTrap 4000; Sciex, Concord, Ontario, Canada) coupled
with an electrospray ionization source to an Ekspert
UltraHPLC 100 (Eksigent, Dublin, CA, USA) with a
Spherisorb ODS2 column (4.6 mm × 250mm× 5 μm)
(Waters). The instrument control, data acquisition, and
lipid mediator quantiﬁcation were performed using Ana-
lyst 1.5.2 software (Sciex). Mass spectrometry was carried
out in negative ion mode using speciﬁc transitions 327/
287 and 327/229. Calibration curves were constructed
with an internal standard 332/288 and r values of curves
were > 0.99 in all cases. DHA and AA (Sigma D2534 and
A9673) were used as standard in the LC-MS/MS.
Cell culture
Cells were grown at 37 °C in a 5% CO2 atmosphere.
Human Lx2 cell line was kindly provided by S. Friedman
(Mount Sinai hospital, NY) and cultured in Dulbecco's
Modiﬁed Eagle's Medium supplemented with 2 mM glu-
tamine, 100 μg/ml penicillin/streptomycin and 2% fetal
bovine serum (FBS). Primary mHSCs were isolated from
16-week-old C57 healthy mice as described54. Brieﬂy,
mouse livers were digested with Pronase E (Sigma
000000010165921001) and Collagenase P (Sigma C5138)
using a perfusion system. A Nycodenz (Sigma D2158)
density gradient was used to separate other liver cells
from HSCs, which have low density due to their high lipid
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content. Vitamin A autoﬂuorescence and fat-storing
characteristics were used to certify that the purity of the
HSC population was higher than 95%. Primary mHSCs
were cultured in DMEN-F12, 10% SFB, 100 μg/ml peni-
cillin/streptomicin and 1% fungizone. The media was
replaced every other day. When indicated, cells were
incubated with TGFβ (RyD 240-B-002), TNFα (Prepotech
300-01 A) or the following fatty acids resuspended in
DMSO (Sigma D4540): DHA (Sigma D2534), DPA (SC-
200786), EPA (Sigma E2011) and palmitic acid (Sigma
P5585). After resuspension in DMSO, the proper dose of
fatty acids was mixed thoroughly with cell media con-
taining FBS and added to the cells.
Cell proliferation assays
Lx2 cells were plated in 96-well plates at 4000 cells/well,
and the following day the treatment to be tested was
added in a ﬁnal volume of 100 μl. Cell viability was
measured after 24, 48 and 96 h using the MTT assay.
Brieﬂy, 10 μl of MTT stock solution (5 mg/ml) was added
to each well and cells were incubated for 4 h at 37 °C in an
atmosphere of 5% of O2. Then, the medium was removed,
100 μl of DMSO-Isopropanol (1:1, v/v) was added and the
absorbance was measured at 540 and 630 nm. The latter
was considered background and was subtracted from the
540-nm measurement.
Oil red staining
Lx2 cells were plated on four-well chambers (LabTek) at
20000 cells/well and treated as described. The following
day, cells were ﬁxed with 10% paraformaldehyde (PFA) for
15min, dehydrated with 1,2-propanediol (Sigma 398039)
for 5 min, stained with pre-warmed Oil Red O solution
(Sigma O1516) for 10min at 60 °C and incubated with
85% 1,2-propanediol solution for 5 min. Then, prepara-
tions were rinsed twice in distilled water, treated with
Gill’s or Mayer’s hematoxylin to stain nuclei and washed
twice in water for 3 min.
Plasmid transfections and luciferase reporter assays
For overexpression experiments, p65 and p65-S536A
plasmids were kindly provided by Carl Sasaki55 and
pIKKb-ON plasmid was obtained from Addgene (Ref.
11105). Lx2 cells were seeded 24 h prior transfection at
170,000 cells/well in six-well plates. Transfection was
done with 0.6 μg total DNA mixed with 1.2 μl Lipofecta-
mine 3000 following the manufacturer’s instructions
(Invitrogen, New York, NY, USA). The media was
replaced 24 h later and the overexpression was assessed by
quantitative real-time polymerase chain reaction (qRT-
PCR) and western blot. For luciferase reporter assays,
SBE4-Luc (Addgene, 16495) and pRL-CMV (Promega)
were used. Lx2 cells were seeded 24 h prior transfection at
75,000 cells/well in 12-well plates. Transfection was done
with 0.5 μl Lipofectamine 3000 mixed with 0.05 μg CMV-
Renilla and 0.2 μg pSBE-Luc. One day later cells were
treated as described (DMSO, 30 μM DHA, 7.5 ng/ml
TGFβ) for 24 h, and Renilla and Fireﬂy luciferase activities
were measured using the Dual Luciferase System (Pro-
mega) according to the manufacturer’s instructions in a
Berthold Luminometer (Lumat LB 9507). The values
obtained for Fireﬂy luciferase were corrected for equal
transfection efﬁciency with those for Renilla luciferase.
RNA extraction and qRT-PCR
Total RNA from tissue or cells was isolated using the
Maxwell® 16 LEV simply RNA Puriﬁcation Kit (Promega)
and reverse transcription was carried out with SuperScript
II reverse transcriptase (Invitrogen). Messenger RNA
levels were determined by qRT-PCR using the SYBR®
Green Supermix Reagent (Bio-Rad). Gene expression was
normalized to the RPLP0 housekeeping gene and
expressed as 2-ΔCT or 2-ΔΔCT, when several experiments
were grouped. All primer sequences are listed in Sup-
plementary Table 2.
Expression arrays from Lx2 and primary mouse HSCs
Lx2 cells were treated with DMSO, 50 µM palmitic acid
or 50 µM DHA for 48 h. Primary mHSCs were isolated
from mice, cultured in six-well plates for 3 days and
treated with DMSO or 100 µM DHA for 48 h. Total RNA
was isolated from three independent samples using the
Maxwell® 16 LEV simply RNA Puriﬁcation Kit (Promega),
and RNA quantity and quality were determined using a
nanodrop (Thermo Scientiﬁc, Waltham, MA, USA) and
Bioanalyzer (Agilent Inc., Santa Clara, CA, USA). Excel-
lent quality samples were hybridized to the Human gene
2.0 (Affymetrix) or the GeneChip® Mouse Gene 2.0
(Affymetrix). The methods used for sample preparation,
hybridization and data analysis were based on the
Affymetrix GeneChip Expression Analysis Manual
(Affymetrix, Santa Clara, CA, USA). Microarray data
normalization was performed using the quantile algo-
rithm and analyzed as described56. The biological
knowledge extraction was complemented using the
Ingenuity Pathway Analysis (Ingenuity Systems, www.
ingenuity.com). Differentially expressed genes (B > 0)
were scrutinized to identify the altered top canonical
pathways and the top upstream regulators. All tran-
scriptome data are available at the NCBI Gene Expression
Omnibus (GEO) data repository (http://www.ncbi.nlm.
nih.gov/geo).
Protein extraction and western blot analyses
For nuclear/cytoplasmic fractionation, cells were sus-
pended in 200 μl of Levrero buffer (50 mM Tris HCl (pH
7.5), 1 mM EDTA, 1% NP-40) containing protease inhi-
bitor cocktail (Roche) and phosphatase inhibitors (10 nM
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NaF and 10 nM NaVO4) and incubated in ice for 10min.
Nuclei were separated from the cytosol by centrifugation
at 3000 rpm. Nuclei and total cells were lysed in radio-
immunoprecipitation assay (RIPA) buffer with protease
and phosphatase inhibitors. For western bBlot analyses,
around 10–20 μg protein was loaded per lane of poly-
acrylamide gel. After electrophoresis, proteins were
transferred to polyvinylidene diﬂuoride (PVDF) mem-
branes using the Bio-Rad TransBlot (Bio-Rad, CA, USA).
The membranes were blocked with 1% dried milk+ 4%
BSA in PBS and were incubated with the following pri-
mary antibodies: anti-GAPDH (2118), anti-SMAD3
(9523), anti-phospho-SMAD3 (9520), anti-p65 (8242),
anti-phospho-p65-S536 (3033), anti-IKKB (2684), anti-
IKKα (2682) and anti-phospho-EIF2α (9721) from Cell
Signaling; anti-NRF2 (ab62352) from Abcam and anti-
EIF2α (sc-11386), anti-HDAC2 (sc-7899), anti-IKBα (sc-
371), anti-IKBβ (sc-9130), anti-p50 (sc-7178) and anti-
C23 (sc-515312) from Santa Cruz Biotechnology. Primary
antibodies were detected with the corresponding
peroxidase-linked secondary antibodies, anti-rabbit IgG
(7074, Cell Signaling) and anti-Mouse IgG (A0168,
Sigma). Signal was developed with ECL-plus or ECL-ultra
(Amersham) using the Odissey Li-Cor Hardware. Densi-
tometry of the signal was carried out using Image Studio
Lite v5.0 Software (LI-COR).
Statistical analysis
Statistical analyses were performed using Prism 5
(GraphPad Software). Differences between two groups
were analyzed using Student’s t test or U–Mann Whitney,
whereas differences between three or more groups were
analyzed using the Kruskal–Wallis ANOVA test followed
by Dunn’s multiple comparisons test. MTT assays were
analyzed by two-way ANOVA followed by Bonferroni’s
multiple comparisons test. Results are represented
as mean ± SD. Statistical signiﬁcance is indicated by
***(p < 0.001), **(p < 0.01) or *(p < 0.05). ns indicates non-
signiﬁcant differences.
Acknowledgements
This study was supported by European FEDER funding and grants from the
Ministry of Economy (SAF2015-70971-R), Gobierno de Navarra 0011-1365-2016-
000308, Fundación Echevano, Fundación Unicaja, and Fondo de Investigación
Sanitaria (PI16/02081), ﬁnanced by the Instituto de Salud Carlos III. We
particularly acknowledge the patients for their participation and the Biobank of
the University of Navarra for its collaboration. We thank Carl Sasaki for RelA/p65
plasmids, Fernando Corrales and Leticia Odriozola for MS evaluation, Carlos
Rodriguez and Sara Arcelus for help with mHSC isolation, and Victor Segura
and Eli Guruceaga for bioinformatic analysis of the microarrays.
Author details
1Department of Gene Therapy and Hepatology, Center for Applied Medical
Research (CIMA), University of Navarra (UNAV), Pamplona, Spain. 2Navarra
Institute for Health Research (IdiSNA), Pamplona, Spain. 3Department of
Experimental Medicine, University of Lleida (IRB), Lleida, Spain. 4Liver Unit,
Clínica Universidad de Navarra, Pamplona, Spain. 5Centro de Investigación
Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd),
Pamplona, Spain. 6CIMA/UNAV, Pamplona, Spain
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41419-018-1243-0).
Received: 29 June 2018 Revised: 15 October 2018 Accepted: 16 October
2018
References
1. Sobrevals, L. et al. Insulin-like growth factor I gene transfer to cirrhotic liver
induces ﬁbrolysis and reduces ﬁbrogenesis leading to cirrhosis reversion in
rats. Hepatology 51, 912–921 (2010).
2. Bémeur, C. & Butterworth, R. F. Nutrition in the management of cirrhosis and
its neurological complications. J. Clin. Exp. Hepatol. 4, 141–150 (2014).
3. Suzuki, K., Endo, R. & Kato, A. in Liver Cirrhosis - Update and Current Challenges
(InTech, 2017). https://doi.org/10.5772/intechopen.68828.
4. Rodríguez-Cruz, M. & Serna, D. S. Nutrigenomics of ω-3 fatty acids: Regulators
of the master transcription factors. Nutrition 41, 90–96 (2017).
5. Saini, R. K. & Keum, Y.-S. Omega-3 and omega-6 polyunsaturated fatty acids:
Dietary sources, metabolism, and signiﬁcance - A review. Life. Sci. 203,
255–267 (2018).
6. Watanabe, A., Saito, S., Tsuchida, T., Higuchi, K. & Okita, M. Low plasma levels of
docosahexaenoic acid in patients with liver cirrhosis and its correction with a
polyunsaturated fatty acid-enriched soft oil capsule. Nutrition 15, 284–288
(1999).
7. Ristić-Medić, D. et al. Abnormalities in the serum phospholipids fatty acid
proﬁle in patients with alcoholic liver cirrhosis - a pilot study. J. Clin. Biochem.
Nutr. 53, 49–54 (2013).
8. Huang, W., Wang, B., Li, X. & Kang, J. X. Endogenously elevated n-3 poly-
unsaturated fatty acids alleviate acute ethanol-induced liver steatosis. Biofac-
tors 41, 453–462.
9. Kim, E.-H. H., Bae, J.-S. S., Hahm, K. B. & Cha, J.-Y. Y. Endogenously syn-
thesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat
diet-induced non-alcoholic fatty liver disease. Biochem. Pharmacol. 84,
1359–1365 (2012).
10. López-Vicario, C. et al. Molecular interplay between Δ5/Δ6 desaturases and
long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut
63, 344–355 (2014).
11. Weylandt, K. H. et al. Suppressed liver tumorigenesis in fat-1 mice with ele-
vated omega-3 fatty acids is associated with increased omega-3 derived lipid
mediators and reduced TNF-α. Carcinogenesis 32, 897–903 (2011).
12. Shang, T. et al. Protective effects of various ratios of DHA/EPA supplementa-
tion on high-fat diet-induced liver damage in mice. Lipids Health Dis. 16, 65
(2017).
13. Suzuki-Kemuriyama, N. et al. Different effects of eicosapentaenoic and doc-
osahexaenoic acids on atherogenic high-fat diet-induced non-alcoholic fatty
liver disease in mice. PLoS ONE 11, e0157580 (2016).
14. Depner, C. M., Philbrick, K. A. & Jump, D. B. Docosahexaenoic acid attenuates
hepatic inﬂammation, oxidative stress, and ﬁbrosis without decreasing
hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced non-
alcoholic steatohepatitis. J. Nutr. 143, 315–323 (2013).
15. Lytle, K. A., Wong, C. P. & Jump, D. B. Docosahexaenoic acid blocks progression
of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
PLoS ONE 12, e0173376 (2017).
16. Shaaban, A. A., Shaker, M. E., Zalata, K. R., El-kashef, H. A. & Ibrahim, T. M.
Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury
and ﬁbrosis by olmesartan and omega-3. Chem. Biol. Interact. 207, 81–91
(2014).
Enguita et al. Cell Death and Disease           (2019) 10:14 Page 12 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
17. Christian, F., Smith, E. L. & Carmody, R. J. The Regulation of NF-κB Subunits by
Phosphorylation. Cells 5, 1–19 (2016).
18. Wang, T.-M. et al. Docosahexaenoic acid attenuates VCAM-1 expression and
NF-κB activation in TNF-α-treated human aortic endothelial cells. J. Nutr. Bio-
chem. 22, 187–194 (2011).
19. Acharya, C., Sahingur, S. E. & Bajaj, J. S. Microbiota, cirrhosis, and the emerging
oral-gut-liver axis. JCI insight 2, 1–11 (2017).
20. Costantini, L., Molinari, R., Farinon, B. & Merendino, N. Impact of omega-3 fatty
acids on the gut microbiota. Int. J. Mol. Sci. 18, 1–18 (2017).
21. Strnad, P., Tacke, F., Koch, A. & Trautwein, C. Liver - guardian, modiﬁer and
target of sepsis. Nat. Rev. Gastroenterol. Hepatol. 14, 55–66 (2017).
22. Feng, R. et al. Endogenous n-3 fatty acids alleviate carbon-tetrachloride-
induced acute liver injury in fat-1 transgenic mice. Oxid. Med. Cell. Longev.
2016, 7962948 (2016).
23. González-Périz, A. et al. Docosahexaenoic acid (DHA) blunts liver injury by
conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA.
FASEB J. 20, 2537–2539 (2006).
24. Oh, C. J. et al. Dimethylfumarate attenuates renal ﬁbrosis via NF-E2-related
factor 2-mediated inhibition of transforming growth factor-β/Smad signaling.
PLoS ONE 7, e45870 (2012).
25. Ryoo, I.-G., Ha, H. & Kwak, M.-K. Inhibitory role of the KEAP1-NRF2 pathway in
TGFβ1-stimulated renal epithelial transition to ﬁbroblastic cells: a modulatory
effect on SMAD signaling. PLoS ONE 9, e93265 (2014).
26. Rachakonda, G. et al. Increased cell migration and plasticity in Nrf2-deﬁcient
cancer cell lines. Oncogene 29, 3703–3714 (2010).
27. Jakobsen, C. H. et al. DHA induces ER stress and growth arrest in human colon
cancer cells: associations with cholesterol and calcium homeostasis. J. Lipid Res.
49, 2089–2100 (2008).
28. Chusri, P. et al. HCV induces transforming growth factor β1 through activation
of endoplasmic reticulum stress and the unfolded protein response. Sci. Rep. 6,
22487 (2016).
29. Pozzer, D. et al. Endoplasmic reticulum oxidative stress triggers tgf-beta-
dependent muscle dysfunction by accelerating ascorbic acid turnover. Sci.
Rep. 7, 40993 (2017).
30. Tanjore, H., Lawson, W. E. & Blackwell, T. S. Endoplasmic reticulum stress as a
pro-ﬁbrotic stimulus. Biochim. Biophys. Acta 1832, 940–947 (2013).
31. Stockert, J. et al. Reverse crosstalk of TGFβ and PPARβ/δ signaling identiﬁed by
transcriptional proﬁling. Nucleic Acids Res. 39, 119–131 (2011).
32. Ohsaki, Y., Cheng, J., Suzuki, M., Fujita, A. & Fujimoto, T. Lipid droplets are
arrested in the ER membrane by tight binding of lipidated apolipoprotein B-
100. J. Cell. Sci. 121, 2415–2422 (2008).
33. Shimada, H., Staten, N. R. & Rajagopalan, L. E. TGF-β1 mediated activation of
Rho kinase induces TGF-β2 and endothelin-1 expression in human hepatic
stellate cells. J. Hepatol. 54, 521–528 (2011).
34. Tang, L.-Y. et al. Transforming growth factor-β (TGF-β) directly activates the
JAK1-STAT3 axis to induce hepatic ﬁbrosis in coordination with the SMAD
pathway. J. Biol. Chem. 292, 4302–4312 (2017).
35. Dooley, S. et al. Hepatocyte-speciﬁc Smad7 expression attenuates TGF-beta-
mediated ﬁbrogenesis and protects against liver damage. Gastroenterology
135, 642–659 (2008).
36. Luedde, T. & Schwabe, R. F. NF-κB in the liver–linking injury, ﬁbrosis and
hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 8, 108–118 (2011).
37. Oakley, F. et al. Angiotensin II activates I kappaB kinase phosphorylation of
RelA at Ser 536 to promote myoﬁbroblast survival and liver ﬁbrosis. Gastro-
enterology 136, 2334–2344.e1 (2009).
38. Moles, A. et al. Inhibition of RelA-Ser536 phosphorylation by a competing
peptide reduces mouse liver ﬁbrosis without blocking the innate immune
response. Hepatology 57, 817–828 (2013).
39. Yang, Y.-C. et al. Docosahexaenoic acid inhibition of inﬂammation is partially
via cross-talk between Nrf2/heme oxygenase 1 and IKK/NF-κB pathways.
J. Nutr. Biochem. 24, 204–212 (2013).
40. Rahman, M. M., Bhattacharya, A. & Fernandes, G. Docosahexaenoic acid is
more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than
eicosapentaenoic acid. J. Cell. Physiol. 214, 201–209 (2008).
41. Paterniti, I. et al. Docosahexaenoic acid attenuates the early inﬂammatory
response following spinal cord injury in mice: in-vivo and in-vitro studies.
J. Neuroinﬂamm. 11, 6 (2014).
42. Oh, D. Y. et al. GPR120 is an omega-3 fatty acid receptor mediating potent
anti-inﬂammatory and insulin-sensitizing effects. Cell 142, 687–698
(2010).
43. Hintermann, E., Bayer, M., Pfeilschifter, J. M., Luster, A. D. & Christen, U. CXCL10
promotes liver ﬁbrosis by prevention of NK cell mediated hepatic stellate cell
inactivation. J. Autoimmun. 35, 424–435 (2010).
44. Zhang, X. et al. CXCL10 plays a key role as an inﬂammatory mediator and a
non-invasive biomarker of non-alcoholic steatohepatitis. J. Hepatol. 61,
1365–1375 (2014).
45. Capanni, M. et al. Prolonged n-3 polyunsaturated fatty acid supplementation
ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease:
a pilot study. Aliment. Pharmacol. Ther. 23, 1143–1151 (2006).
46. Spadaro, L. et al. Effects of n-3 polyunsaturated fatty acids in subjects with
nonalcoholic fatty liver disease. Dig. Liver. Dis. 40, 194–199 (2008).
47. Tanaka, N. et al. Highly puriﬁed eicosapentaenoic acid treatment
improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 42, 413–418
(2008).
48. Scorletti, E. et al. Design and rationale of the WELCOME trial: A randomised,
placebo controlled study to test the efﬁcacy of puriﬁed long chainomega-3
fatty acid treatment in non-alcoholic fatty liver disease [corrected]. Contemp.
Clin. Trials 37, 301–311 (2014).
49. Pastor-Clerigues, A., Marti-Bonmati, E., Milara, J., Almudever, P. & Cortijo, J. Anti-
inﬂammatory and anti-ﬁbrotic proﬁle of ﬁsh oil emulsions used in parenteral
nutrition-associated liver disease. PLoS ONE 9, e115404 (2014).
50. Argo, C. K. et al. Effects of n-3 ﬁsh oil on metabolic and histological parameters
in NASH: a double-blind, randomized, placebo-controlled trial. J. Hepatol. 62,
190–197 (2015).
51. Nogueira, M. A. et al. Omega-3 polyunsaturated fatty acids in treating non-
alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
Clin. Nutr. 35, 578–586 (2016).
52. Hodson, L. et al. Docosahexaenoic acid enrichment in NAFLD is associated
with improvements in hepatic metabolism and hepatic insulin sensitivity: a
pilot study. Eur. J. Clin. Nutr. 71, 973–979 (2017).
53. Bligh, EG., Dyer, WJ. A rapid method of total lipid extraction and puriﬁcation.
Can. J. Biochem. Physiol. 37, 911–917 (1959).
54. Weiskirchen, S., Tag, C. G., Sauer-Lehnen, S., Tacke, F. & Weiskirchen, R. Isolation
and culture of primary murine hepatic stellate cells. Methods Mol. Biol. 1627,
165–191 (2017).
55. Sasaki, C. Y., Barberi, T. J., Ghosh, P. & Longo, D. L. Phosphorylation of RelA/p65
on serine 536 deﬁnes an I{kappa}B{alpha}-independent NF-{kappa}B pathway.
J. Biol. Chem. 280, 34538–34547 (2005).
56. Carnero, E. et al. Long noncoding RNA EGOT negatively affects the antiviral
response and favors HCV replication. EMBO Rep. 17, 1013–1028 (2016).
Enguita et al. Cell Death and Disease           (2019) 10:14 Page 13 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
